Expansion of SVN-015 into depression

AI SummaryClose X

Solvonis Therapeutics plc announced the expansion of its investigational compound SVN-015 into depression treatment, following preclinical data demonstrating antidepressant-like activity comparable to fluoxetine after 14-day, once-daily dosing in rodent models. SVN-015 is a novel Serotonin-Dopamine Reuptake Inhibitor designed to target pathways involved in mood, motivation, and reward processing, potentially benefiting patients with inadequate SSRI response, particularly those experiencing anhedonia and reduced motivation. The compound is expected to be developed as a once-daily oral therapy, aligning with standard antidepressant treatment cycles and potentially offering advantages in scalability and patient access.

Disclaimer*

UK 100

Latest directors dealings